Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation ...

According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

Tryptamine Therapeutics (Tryp) has announced the completion of subject dosing in a Phase Ib clinical trial of TRP-8803, for ...

Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported initiation of an expanded part of CAN10's phase 1 clinical study to investigate higher dose levels of the antibody. The purpose of this ...

Alumis Inc. (NASDAQ: ALMS) recently disclosed revisions to its estimates for primary completion and study completion dates ...

Clinical-stage biotech Tryptamine Therapeutics (ASX:TYP) has successfully and safely completed obese-subject dosing in its ...

Detailed price information for Aclaris Therapts (ACRS-Q) from The Globe and Mail including charting and trades.

In a significant development, the pharmaceutical major Dr Reddys Laboratories has got the go-ahead from the Subject Expert ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

On Tuesday, Amgen Inc (NASDAQ:AMGN) stock fell during the premarket session after the company released long-anticipated data ...

Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide ...